Zealand Pharma A/S ((ZLDPF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zealand Pharma A/S is conducting a clinical study titled A First-in-human, Randomized and Double-blind Within Cohorts, Placebo-controlled, Single Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP9830 Administered to Healthy Male Subjects. The study aims to evaluate the safety and tolerability of ZP9830, a drug intended for autoimmune diseases, and understand its behavior in the body compared to a placebo.
The intervention being tested is ZP9830, administered as a single dose either subcutaneously or intravenously. The study involves multiple cohorts with varying doses to assess the drug’s effects.
This interventional study is designed with a randomized allocation and a sequential intervention model. It employs a double-blind masking approach, meaning both participants and investigators are unaware of who receives the active drug or placebo. The primary purpose is treatment-focused.
The study began on November 7, 2024, with the last update submitted on November 13, 2024. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The study’s progress could influence Zealand Pharma’s stock performance and investor sentiment, especially if the results show promising safety and efficacy of ZP9830. This could position the company favorably against competitors in the autoimmune disease treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.